Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.48 |
| ▸ | PDE2A | O00408 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412985 | 0.85 | PDE5A (0.49) | PDE5APDE2AMAPTHTTKMT2A | |
| SCHEMBL5254027 | 0.82 | MAPT (0.46) | PDE5AMEN1MAPTHTTKMT2A | |
| SCHEMBL5412846 | 0.81 | MAPT (0.45) | PDE5AMEN1MAPTHTTKMT2A | |
| SCHEMBL7404512 | 0.81 | MAPT (0.53) | PDE5AMEN1MAPTHTTKMT2A | |
| SCHEMBL5404955 | 0.80 | PDE5A (0.46) | PDE5AMEN1MAPTHTTKMT2A | |
| SCHEMBL6213742 | 0.80 | MAPT (0.44) | PDE5AMEN1MAPTHTTKMT2A | |
| SCHEMBL5417545 | 0.79 | MAPT (0.46) | PDE5AMEN1MAPTHTTKMT2A | |
| SCHEMBL5408026 | 0.78 | MAPT (0.51) | PDE5AMEN1MAPTHTTKMT2A | |
| SCHEMBL8177973 | 0.78 | PDE5A (0.51) | PDE5A | |
| SCHEMBL7171537 | 0.78 | MAPT (0.50) | PDE5AMEN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259168-B2 | 2-Aminoalkyl-thieno[2,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2007-08-21 | — | — | US | claimed |
| EP-1294729-B1 | 2-AMINOALKYL-THIENO[2,3-D]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2004-09-15 | — | — | EP | claimed |
| US-20040044011-A1 | 2-Aminoalkyl-thieno[2,3-d]pyrimidines | MEREK PATENT GMBH (DE) | 2004-03-04 | — | — | US | claimed |
| EP-1294729-A1 | 2-AMINOALKYL-THIENO[2,3-D]PYRIMIDINES | MERCK PATENT GmbH (DE) | 2003-03-26 | — | — | EP | claimed |
| WO-2002000664-A1 | 2-AMINOALKYL-THIENO[2,3-D]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2002-01-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044011-A1 | 2-Aminoalkyl-thieno[2,3-d]pyrimidines | DPYD, PDE3A, PDE2A | PDE5A 6/4885PDE2A 3/4885MEN1 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.